Therapeutic Use of Mesenchymal Stromal Cells: The Need for Inclusive Characterization Guidelines to Accommodate All Tissue Sources and Species
| Autor: | Adrienne Wright, Marne L. Arthaud-Day, Mark L. Weiss |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Standard of care business.industry Mesenchymal stem cell Cell Biology Review metrology and characterization Preclinical data Food and drug administration Clinical trial MSC Cell and Developmental Biology lcsh:Biology (General) clinical translation challenge Medicine business Intensive care medicine biotherapeutic development lcsh:QH301-705.5 commercialization Developmental Biology |
| Zdroj: | Frontiers in Cell and Developmental Biology, Vol 9 (2021) Frontiers in Cell and Developmental Biology |
| ISSN: | 2296-634X |
| Popis: | Following their discovery over 50 years ago, mesenchymal stromal cells (MSCs) have become one of the most studied cellular therapeutic products by both academia and industry due to their regenerative potential and immunomodulatory properties. The promise of MSCs as a therapeutic modality has been demonstrated by preclinical data yet has not translated to consistent, successful clinical trial results in humans. Despite the disparities across the field, MSC shareholders are unified under one common goal—to use MSCs as a therapeutic modality to improve the quality of life for those suffering from a malady in which the standard of care is suboptimal or no longer effective. Currently, there is no Food and Drug Administration (FDA)-approved MSC therapy on the market in the United States although several MSC products have been granted regulatory approval in other countries. In this review, we intend to identify hurdles that are impeding therapeutic progress and discuss strategies that may aid in accomplishing this universal goal of widespread therapeutic use. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|